Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Infectious Disease Partnering Head Patrick Schleck Describes Priorities
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Join us for a brief audio tour around the past week's major biopharma industry developments, as reported by Scrip's global team.